Abstract:Background: While irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal diseases in clinical practice, it has diverse pathogenesis. Because of its sudden and lingering intractable symptoms, it seriously affects patients work and life. Opioid receptors are G protein-coupled receptors distributed across the brain, spinal cord, skin, and gastrointestinal tract, and each of the subtypes has a unique role and specific distribution. They play a role in regulating gastrointestinal motility, secretion, and visceral sensations in the gastrointestinal tract. Therefore, this meta-analysis aims to evaluate the effects of opioid receptor modulators on improving the symptoms of IBS. Methods: Searching the key words (Irritable Bowel Syndromes or Syndrome, Irritable Bowel OR Syndromes, Irritable Bowel OR Colon, Irritable OR Irritable Colon OR Colitis, Mucous OR Colitides, Mucous OR Mucous Colitides OR Mucous Colitis) AND (opioid receptor modulators OR eluxadoline OR Viberzi OR asimadoline OR loperamide), a preliminary search on PubMed (English), EMBASE (English), Cochrane Library (English), China National Knowledge Infrastructure Database (CNKI, Chinese), WanFang (Chinese), VIP citation databases (Chinese) and SinoMed (Chinese) databases yielded 1023 papers published in English and Chinese from inception to July 1, 2019. Nine studies were included in the final meta-analysis. Because this is a systematic review and meta-analysis, ethical approval is not necessary. Results: The random-effects meta-analysis based on these 9 studies and their 4156 patients found that opioid receptor modulators have a statistically significant beneficial effect on IBS global symptoms (RR = 0.85, 95%CI = 0.79-0.92, P < .01) and bowel movement frequency (SMD = -1.26, 95%CI = -2.49--0.04, P < .05), and while there was an improvement trend in stool consistency and quality of life, these findings were not statistically significant. Conclusions: This is the first meta-analysis to examine the use of opioid receptor modulators in IBS, and few adverse events were reported in the available trials. Compared with the control group, eluxadolin has a better effect in improving IBS global symptoms and abdominal pain and has statistical significance and showed a low rate of constipation development in IBS patients in comparison with known effects of other opioid receptor modulators. However, current findings are based on a considerably limited evidence base with marked heterogeneity. Future studies should aim to identify subpopulations of patients with IBS and need to evaluate the long-term safety of these therapies.PROSPERO registration number: CRD42020141597.

Efficacy and Safety of Otilonium Bromide for Irritable Bowel Syndrome

Treatment of Irritable Bowel Syndrome with Drotaverine Hydrochloride: A Multicentre Clinical Trial

Effects of Treatments with Otilonium Bromide, Colloidal BismuthTartrate and Compound Diphenoxylate in the Irritable Bowel Syndrome: A Double-blind Random Controlled Study

Effects of otilonium bromide on anorectal visceral sensorimotor functions of patients with diarrhea-predominant irritable bowel syndrome

SF-36 quality of life in effectiveness ssessment for irritable bowel syndrome

Clinical Efficacy of Glutamine in the Treatment of Irritable Bowel Syndrome

Pinaverium Bromide Combined with Bifid Triple Viable and Doxepin Therapy in Diarrhea-Dominant Irritable Bowel Syndrome

Assessment of Efficacy of Pinaverium Bromide in Treatment of Irritable Bowel Syndrome and Its Effect on Visceral Motility and Sensitivity

Effect of herbal extract granules combined with otilonium bromide on irritable bowel syndrome with diarrhoea: a study protocol for a randomised controlled trial

Colonic smooth muscle cells and colonic motility patterns as a target for irritable bowel syndrome therapy: mechanisms of action of otilonium bromide

Efficacy and Safety of Calcium Polycarbophil in the Treatment of Constipation-Predominant Irritable Bowel Syndrome

A Mini Review on Characteristics and Analytical Methods of Otilonium Bromide

Effect of Samryungbaekchul-san Combined with Otilonium Bromide on Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Randomized Controlled Trial

Otilonium Bromide Prevents Cholinergic Changes in the Distal Colon Induced by Chronic Water Avoidance Stress, a Rat Model of Irritable Bowel Syndrome

Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis

A Probiotic Treatment Containing Lactobacillus, Bifidobacterium and Enterococcus Improves IBS Symptoms in an Open Label Trial

Clinical Efficacy of Different Drugs on Irritable Bowel Syndrome

Repeated otilonium bromide administration prevents neurotransmitter changes in colon of rats underwent to wrap restraint stress

Role of antispasmodics in the treatment of irritable bowel syndrome

Efficacy of opioid receptor modulators in patients with irritable bowel syndrome: A systematic review and meta-analysis

A clinical trail of probiotics in the treatment of IBS-D